The company’s 50 day moving average is $8.35 and its two-hundred day moving average is $13.04. CervoMed Inc. has a twelve ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders ...

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy ...

Dec 10 (Reuters) - CervoMed (CRVO.O), opens new tab said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical ...

D. Boral Capital downgraded CervoMed (CRVO) to Hold from Buy and removed the firm’s prior price target after the company reported that the Phase 2b RewinD-LB trial of neflamapimod in dementia ...

Shares of CervoMed Inc. (NASDAQ:CRVO – Get Free Report) have been assigned an average recommendation of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports ...

There are 118 funds or institutions reporting positions in CervoMed. This is an increase of 64 owner(s) or 118.52% in the last quarter. Average portfolio weight of all funds dedicated to CRVO is 0 ...

(RTTNews) - CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies or DLB failed to demonstrate ...

CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26 ...

A midstage trial of a treatment for patients with dementia with Lewy bodies failed to meet its main goals CervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage ...